biostudies-literatureUnknown28(11)Chaparro MJanssen-Cilag Spain<h4>Background</h4>Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn's disease (CD) patients in real-world clinical practice.<h4>Methods</h4>A retrospective, multicentre study was conducted in Spain in patients with active CD who had received ≥1 intravenous dose of ustekinumab for ≥6 months. Primary outcome was ustekinumab retention rate; secondary outcomes were to identify predictive factors for drug retention, short-term remission (week 16), loss of response and predictive factors for short-term efficacy and loss of response, and ustekinumab safety.<h4>Results</h4>A total of 463 patients were included. Mean baseline Harvey-Bradshaw Index was 8.4. A total of 447 (96.5%) patients had received prior biologInflammatory bowel diseases1725-1736https://www.ebi.ac.uk/biostudies/studies/S-EPMC9629456biostudies-literatureLong-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.PMC9629456Arroyo MGonzalez Garcia JVarela PGutierrez Casbas AFradejas Salazar PMonfort DGinard DDiz-Lois Palomares MTRobles Alonso VBusquets DVan Domselaar MArguelles-Arias FDuenas Sadornil CBermejo FMartinez Cadilla JHervias Cruz DIyo EQuilez Ivorra CRubio Iturria SGarcia Lopez Sde Francisco RGisbert JPVelayos Jimenez BBaston-Rey IFiguerola AGonzalez-Lama YMartinez Cerezo FJAmo VMMolina Arriero GMartin-Arranz MDCamo-Monterde PGarcia Tercero IHernandez Camba ACharro MNunez Ortiz ASulleiro SHinojosa EGordillo JMartinez Montiel PRodriguez Moranta FChaparro MRubin de Celix CMerino Ochoa OCabello MBosca-Watts MMVazquez Moron JMMarin-Jimenez IMaria Huguet JVispo EIglesias Flores ETaxonera CGarcia MJNovella CArias Garcia LBarreiro-de Acosta MFernandez-Salgado ERamirez de la Piscina PMunagorri Santos AISan Roman ALRamos LJimenez IGarcia-Alonso FJNunez AJimenez NPajares Villarroya RMartin Rodriguez MDMNavarro Llavat MfalseLong-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.<h4>Background</h4>Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn's disease (CD) patients in real-world clinical practice.<h4>Methods</h4>A retrospective, multicentre study was conducted in Spain in patients with active CD who had received ≥1 intravenous dose of ustekinumab for ≥6 months. Primary outcome was ustekinumab retention rate; secondary outcomes were to identify predictive factors for drug retention, short-term remission (week 16), loss of response and predictive factors for short-term efficacy and loss of response, and ustekinumab safety.<h4>Results</h4>A total of 463 patients were included. Mean baseline Harvey-Bradshaw Index was 8.4. A total of 447 (96.5%) patients had received prior biolog2022-01-01T00:00:00Z2022 Nov2025-04-05T11:57:27.428Z2025-04-05T11:57:27.428ZS-EPMC96294563516634710.1093/ibd/izab357